



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/47, C12N 15/70, 1/21, A61K 38/17, C07K 16/18, C12Q 1/68		AI	(11) International Publication Number: WO 99/23220
			(43) International Publication Date: 14 May 1999 (14.05.99)
(21) International Application Number: PCT/US98/22930		(74) Agents: BILLINGS, Lucy, J. et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).	
(22) International Filing Date: 28 October 1998 (28.10.98)			
(30) Priority Data: 08/963,165 3 November 1997 (03.11.97) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/963,165 (CIP) Filed on 3 November 1997 (03.11.97)		Published With international search report. Before the expiration of the time limits for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): HILLMAN, Jennifer, L. [US/US]; 230 Monroe Drive #12, Mountain View, CA 94040 (US). SHAH, Purvi [IN/US]; 1608 Queen Charlotte Drive #5, Sunnyvale, CA 94087 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US).			
(54) Title: SUPPRESSOR OF CYTOKINE SIGNALING			
<p>9 18 27 36 45 54 AAG TGN CCG CTG TGN ANG NGC CNG ATN NGC GGA GGC CGC GAA CAG CTG CAG CCG</p> <p>63 72 81 90 99 109 CCG CCG CGC AGA TCC ACG CTG GCT CCG TGC GCC ATG GTC ACC CAC AGC AAG TTT M V T H S K F</p> <p>117 126 135 144 153 162 CCC GCC GGC GGG ATG AGC CGC CCC CTG GAC ACC AGC CTG CGC CTC AAG ACC TTC P A A G M S R P L D T S L R L K T F</p> <p>171 180 189 198 207 216 AGC TCC AAG AGC GAG TAC CAG CTG GTG AAC GCA GTG CGC AAG CTG CAG GAG S S K S E Y Q L V V N A V R K L Q E</p> <p>225 234 243 252 261 270 AGC GGC TTC TAC TGG AGC GCA GTG ACC GGC GGC GAG CGC AAC CTG CTG CTC AGT S G F Y W S A V T G G E A N L L L S</p> <p>279 288 297 306 315 324 GCC GAG CCC GGC GGC ACC TTT CTG ATC CGC GAC AGC TCG GAC CAG CGC CAC TTC A E P A G T F L I R D S S D Q R H F</p> <p>333 342 351 360 369 378 TTC ACG CTC AGC GTC AAG ACC CAG TCT GCG ACC AAG AAC CTG CGC ATC CAG TGT P T L S V K T Q S G T K N L R I Q C</p>			
(57) Abstract			
<p>The invention provides a human suppressor of cytokine signaling (HSCS-1) and polynucleotides which identify and encode HSCS-1. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HSCS-1.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SUPPRESSOR OF CYTOKINE SIGNALING

TECHNICAL FIELD

5 This invention relates to nucleic acid and amino acid sequences of a suppressor of cytokine signaling and to the use of these sequences in the diagnosis, prevention, and treatment of cancer and immune disorders.

BACKGROUND OF THE INVENTION

10 Signal transduction is the general process by which cells respond to extracellular signals (hormones, neurotransmitters, growth and differentiation factors, etc.) through a cascade of biochemical reactions that begins with the binding of the signal molecule to a cell membrane receptor and ends with the activation of an intracellular target molecule. Intermediate steps in this process involve the activation of various cytoplasmic proteins by
15 phosphorylation via protein kinases and the eventual translocation of some of these activated proteins to the cell nucleus where the transcription of specific genes is triggered. Thus signal transduction process regulates all types of cell functions including cell proliferation, differentiation, and gene transcription.

 Cytokines are a specific class of extracellular signaling molecules that control
20 growth, differentiation, and various functions of hemopoietic and immune cells. Cytokines include the interleukins (ILs), colony-stimulating factors (G-CSF and GM-CSF), erythropoietin (EPO), and various growth factors (EGF, PDGF, TGF, and FGF; Callard, R. and Gearing, A. (1994) The Cytokine Facts Book, pp 2-6, Academic Press, San Diego, CA).

25 Many of the cytokine receptors, including those for the growth factors EGF, PDGF, and FGF exhibit intrinsic protein kinase activities. When the cytokine binds to the receptor, it triggers the autophosphorylation of a tyrosine residue on the receptor. It is believed that these phosphorylated sites are recognition sites for the binding of other cytoplasmic signaling proteins in the signaling pathway that eventually links the initial
30 receptor activation at the cell surface to the activation of a specific intracellular target molecule. These signaling proteins contain a common domain, a src homology 2 (SH2)

domain, that is a recognition and binding site for the phosphotyrosine residue. SH2 domains are found in a variety of signaling molecules and oncogenic proteins such as phospholipase C- γ , Ras GTP-ase activating protein, and GRB2 (Lowenstein, E.J. et al. (1992) Cell 70:431-42).

5 While much is known about key events in the activation of signaling pathways, less is known about how they are switched off. Recently, several SH2-containing proteins have been identified that are induced in murine lymphoid cells by various cytokines, including IL-2, IL-3, IL-6, Interferon- γ , and EPO (Yoshimura, A. et al. (1995) EMBO Journal 14:2816-26; Starr, R. et al. (1997) Nature 387: 917-921; and Naka, T. et al. (1997) 10 Nature 387: 924-29). A common property of these proteins is their ability to suppress growth and differentiation in murine cells. The induction of these SH2-containing proteins in cytokine stimulated cells suggests that they may function as negative regulators of cytokine signaling. Transcription of the genes encoding four of these proteins, CIS (cytokine-inducible SH2-containing protein), and SOCS-1, -2, and -3 (suppressor of 15 cytokine signaling), is induced by IL-6 both *in vitro* and *in vivo* (Starr et al., supra).

The four proteins share little sequence homology in their N-terminal regions, but all contain a central SH2 domain and a conserved C-terminal region designated the "SOCS box". The function of the SOCS box is unknown, however a conserved core triplet sequence (K/R) (D/E) (Y/F) is similar to the tyrosine phosphorylation site in the JAK 20 kinase family. This similarity suggests that the SOCS box may provide a site for interaction with, and inhibition of, JAK kinases. The finding that SOCS-1 interacts with the catalytic region of JAK kinases supports this hypothesis (Endo, T. A. et al. (1997) Nature 387: 921-24). Constitutive expression of SOCS-1 in M1 murine lymphoid cells also inhibits the phosphorylation of certain cell signaling components (gp130 and Stat3) in 25 response to IL-6 (Starr et al., supra). CIS binds to tyrosine-phosphorylated residues in the beta-chain of the IL-3 and EPO receptors and provides another possible mechanism for suppressing cell signaling by preventing the binding of other signaling proteins (Yoshimura et al., supra).

Defects or alterations in the activity of signaling proteins such as CIS may play 30 arole in the development of various proliferative disorders and diseases such as cancer. Loss of, or rearrangement of, the putative human gene encoding CIS is associated with the development of renal cell carcinomas and lung cancer (Yoshimura et al., supra). This

association suggests that CIS may function as a tumor suppressor gene.

The discovery of a new suppressor of cytokine signaling and the polynucleotides encoding it satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention and treatment of cancer and immune disorders.

5

SUMMARY OF THE INVENTION

The invention features a substantially purified polypeptide, suppressor of cytokine signaling (HSCS-1), having the amino acid sequence shown in SEQ ID NO:1, or fragments thereof.

10 The invention further provides an isolated and substantially purified polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof and a composition comprising said polynucleotide sequence. The invention also provides a polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence encoding the amino acid sequence SEQ ID
15 NO:1, or fragments of said polynucleotide sequence. The invention further provides a polynucleotide sequence comprising the complement of the polynucleotide sequence encoding the amino acid sequence of SEQ ID NO:1, or fragments or variants of said polynucleotide sequence.

The invention also provides an isolated and purified sequence comprising SEQ ID
20 NO:2 or variants thereof. In addition, the invention provides a polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of SEQ ID NO:2. The invention also provides a polynucleotide sequence comprising the complement of SEQ ID NO:2, or fragments or variants thereof.

The present invention further provides an expression vector containing at least a
25 fragment of any of the claimed polynucleotide sequences. In yet another aspect, the expression vector containing the polynucleotide sequence is contained within a host cell.

The invention also provides a method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment thereof, the method comprising the steps of: a) culturing the host cell containing an expression vector containing at least a
30 fragment of the polynucleotide sequence encoding HSCS-1 under conditions suitable for the expression of the polypeptide; and b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified HSCS-1 having the amino acid sequence of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.

The invention also provides a purified antagonist of the polypeptide of SEQ ID NO:1. In one aspect the invention provides a purified antibody which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:1.

Still further, the invention provides a purified agonist of the polypeptide of SEQ ID NO:1.

The invention also provides a method for treating or preventing cancer comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising purified HSCS-1.

The invention also provides a method for treating or preventing an immune disorder comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising purified HSCS-1

The invention also provides a method for detecting a polynucleotide which encodes HSCS-1 in a biological sample comprising the steps of: a) hybridizing the complement of the polynucleotide sequence which encodes SEQ ID NO:1 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and b) detecting the hybridization complex, wherein the presence of the complex correlates with the presence of a polynucleotide encoding HSCS-1 in the biological sample. In one aspect the nucleic acid material of the biological sample is amplified by the polymerase chain reaction prior to hybridization.

BRIEF DESCRIPTION OF THE FIGURES

Figures 1A, 1B, 1C, 1D, 1E, and 1F show the amino acid sequence (SEQ ID NO:1) and nucleic acid sequence (SEQ ID NO:2) of HSCS-1. The alignment was produced using MacDNASIS PRO™ software (Hitachi Software Engineering Co. Ltd. San Bruno, CA).

Figure 2 shows the amino acid sequence alignments between HSCS-1 (2508270; SEQ ID NO:1), and a suppressor of cytokine signaling, SOCS-3, from mouse (GI 2245388; SEQ ID NO:3) produced using the multisequence alignment program of DNASTAR™ software (DNASTAR Inc, Madison WI).

Figures 3A and 3B show the hydrophobicity plots for HSCS-1 (SEQ ID NO: 1),

and mouse SCOS-3 (SEQ ID NO:3), respectively ; the positive X axis reflects amino acid position, and the negative Y axis, hydrophobicity (MacDNASIS PRO software).

DESCRIPTION OF THE INVENTION

5 Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only
10 by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a host cell" includes a plurality of such host cells, reference to the "antibody" is a reference to one or more antibodies and equivalents thereof
15 known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the
20 preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies which are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior
25 invention.

DEFINITIONS

HSCS-1, as used herein, refers to the amino acid sequences of substantially purified HSCS-1 obtained from any species, particularly mammalian, including bovine,
30 ovine, porcine, murine, equine, and preferably human, from any source whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist", as used herein, refers to a molecule which, when bound to HSCS-1, increases or prolongs the duration of the effect of HSCS-1. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of HSCS-1.

5 An "allele" or "allelic sequence", as used herein, is an alternative form of the gene encoding HSCS-1. Alleles may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to alleles are
10 generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding HSCS-1 as used herein include those with deletions, insertions, or substitutions of different nucleotides resulting in a
15 polynucleotide that encodes the same or a functionally equivalent HSCS-1. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding HSCS-1, and improper or unexpected hybridization to alleles, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding HSCS-1. The encoded
20 protein may also be "altered" and contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent HSCS-1. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the biological or immunological activity of HSCS-1 is retained. For
25 example, negatively charged amino acids may include aspartic acid and glutamic acid; positively charged amino acids may include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine, and valine, glycine and alanine, asparagine and glutamine, serine and threonine, and phenylalanine and tyrosine.

30 "Amino acid sequence" as used herein refers to an oligopeptide, peptide, polypeptide, or protein sequence, and fragment thereof, and to naturally occurring or synthetic molecules. Fragments of HSCS-1 are preferably about 5 to about 15 amino acids

in length and retain the biological activity or the immunological activity of HSCS-1.

Where "amino acid sequence" is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, amino acid sequence, and like terms, are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited protein molecule.

"Amplification" as used herein refers to the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction (PCR) technologies well known in the art (Dieffenbach, C.W. and G.S. Dveksler (1995) PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview, NY).

10 The term "antagonist" as used herein, refers to a molecule which, when bound to HSCS-1, decreases the amount or the duration of the effect of the biological or immunological activity of HSCS-1. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies or any other molecules which decrease the effect of HSCS-1.

As used herein, the term "antibody" refers to intact molecules as well as fragments thereof, such as Fa, F(ab')₂, and Fv, which are capable of binding the epitopic determinant. Antibodies that bind HSCS-1 polypeptides can be prepared using intact polypeptides or fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal can be derived from the translation of RNA or synthesized chemically and can be conjugated to a carrier protein, if
15
20 desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin and thyroglobulin, keyhole limpet hemocyanin. The coupled peptide is then used to immunize the animal (e.g., a mouse, a rat, or a rabbit).

The term "antigenic determinant", as used herein, refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the
25 protein may induce the production of antibodies which bind specifically to a given region or three-dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

30 The term "antisense", as used herein, refers to any composition containing nucleotide sequences which are complementary to a specific DNA or RNA sequence. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary

to the "sense" strand. Antisense molecules include peptide nucleic acids and may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and block either transcription or translation. The designation "negative" is sometimes used in reference to the antisense strand, and "positive" is sometimes used in reference to the sense strand.

The term "biologically active", as used herein, refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic HSCS-1, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

The terms "complementary" or "complementarity", as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base-pairing. For example, the sequence "A-G-T" binds to the complementary sequence "T-C-A". Complementarity between two single-stranded molecules may be "partial", in which only some of the nucleic acids bind, or it may be complete when total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands and in the design and use of PNA molecules.

A "composition comprising a given polynucleotide sequence" as used herein refers broadly to any composition containing the given polynucleotide sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding HSCS-1 (SEQ ID NO:1) or fragments thereof (e.g., SEQ ID NO:2 and fragments thereof) may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., SDS) and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus", as used herein, refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, has been extended using XL-PCR™ (Perkin Elmer,

Norwalk, CT) in the 5' and/or the 3' direction and resequenced, or has been assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly (e.g., GELVIEW™ Fragment Assembly system, GCG, Madison, WI). Some sequences have been both extended and assembled to produce the consensus
5 sequence .

The term "correlates with expression of a polynucleotide", as used herein, indicates that the detection of the presence of ribonucleic acid that is similar to SEQ ID NO:2 by northern analysis is indicative of the presence of mRNA encoding HSCS-1 in a sample and thereby correlates with expression of the transcript from the polynucleotide encoding
10 the protein.

A "deletion", as used herein, refers to a change in the amino acid or nucleotide sequence and results in the absence of one or more amino acid residues or nucleotides.

The term "derivative", as used herein, refers to the chemical modification of a nucleic acid encoding or complementary to HSCS-1 or the encoded HSCS-1. Such
15 modifications include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative encodes a polypeptide which retains the biological or immunological function of the natural molecule. A derivative polypeptide is one which is modified by glycosylation, pegylation, or any similar process which retains the biological or immunological function of the polypeptide from which it was derived.

20 The term "homology", as used herein, refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity). A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to using the functional term "substantially homologous." The inhibition of hybridization of the completely complementary sequence
25 to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or hybridization probe will compete for and inhibit the binding of a completely homologous sequence to the target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-
30 specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a

partial degree of complementarity (e.g., less than about 30% identity). In the absence of non-specific binding, the probe will not hybridize to the second non-complementary target sequence.

Human artificial chromosomes (HACs) are linear microchromosomes which may
5 contain DNA sequences of 10K to 10M in size and contain all of the elements required for stable mitotic chromosome segregation and maintenance (Harrington, J.J. et al. (1997) *Nat Genet.* 15:345-355).

The term "humanized antibody", as used herein, refers to antibody molecules in which amino acids have been replaced in the non-antigen binding regions in order to more
10 closely resemble a human antibody, while still retaining the original binding ability.

The term "hybridization", as used herein, refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

The term "hybridization complex", as used herein, refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between
15 complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (e.g., C_{60} or R_{60} analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized
20 on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

An "insertion" or "addition", as used herein, refers to a change in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, as compared to the naturally occurring molecule.

25 "Microarray" refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support.

The term "modulate", as used herein, refers to a change in the activity of HSCS-1. For example, modulation may cause an increase or a decrease in protein activity, binding
30 characteristics, or any other biological, functional or immunological properties of HSCS-1.

"Nucleic acid sequence" as used herein refers to an oligonucleotide, nucleotide, or polynucleotide, and fragments thereof, and to DNA or RNA of genomic or synthetic origin

which may be single- or double-stranded, and represent the sense or antisense strand. "Fragments" are those nucleic acid sequences which are greater than 60 nucleotides in length, and most preferably includes fragments that are at least 100 nucleotides or at least 1000 nucleotides, and at least 10,000 nucleotides in length.

5 The term "oligonucleotide" refers to a nucleic acid sequence of at least about 6 nucleotides to about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20 to 25 nucleotides, which can be used in PCR amplification or a hybridization assay, or a microarray. As used herein, oligonucleotide is substantially equivalent to the terms "amplimers", "primers", "oligomers", and "probes", as commonly
10 defined in the art.

 "Peptide nucleic acid", PNA as used herein, refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least five nucleotides in length linked to a peptide backbone of amino acid residues which ends in lysine. The terminal lysine confers solubility to the composition. PNAs may be pegylated to extend their
15 lifespan in the cell where they preferentially bind complementary single stranded DNA and RNA and stop transcript elongation (Nielsen, P.E. et al. (1993) Anticancer Drug Des. 8:53-63).

 The term "portion", as used herein, with regard to a protein (as in "a portion of a given protein") refers to fragments of that protein. The fragments may range in size from
20 five amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a protein "comprising at least a portion of the amino acid sequence of SEQ ID NO:1" encompasses the full-length HSCS-1 and fragments thereof.

 The term "sample", as used herein, is used in its broadest sense. A biological sample suspected of containing nucleic acid encoding HSCS-1, or fragments thereof, or
25 HSCS-1 itself may comprise a bodily fluid, extract from a cell, chromosome, organelle, or membrane isolated from a cell, a cell, genomic DNA, RNA, or cDNA (in solution or bound to a solid support, a tissue, a tissue print, and the like).

 The terms "specific binding" or "specifically binding", as used herein, refers to that interaction between a protein or peptide and an agonist, an antibody and an antagonist.
30 The interaction is dependent upon the presence of a particular structure (i.e., the antigenic determinant or epitope) of the protein recognized by the binding molecule. For example, if an antibody is specific for epitope "A", the presence of a protein containing epitope A

(or free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody.

The terms "stringent conditions" or "stringency", as used herein, refer to the conditions for hybridization as defined by the nucleic acid, salt, and temperature. These conditions are well known in the art and may be altered in order to identify or detect identical or related polynucleotide sequences. Numerous equivalent conditions comprising either low or high stringency depend on factors such as the length and nature of the sequence (DNA, RNA, base composition), nature of the target (DNA, RNA, base composition), milieu (in solution or immobilized on a solid substrate), concentration of salts and other components (e.g., formamide, dextran sulfate and/or polyethylene glycol), and temperature of the reactions (within a range from about 5°C below the melting temperature of the probe to about 20°C to 25°C below the melting temperature). One or more factors may be varied to generate conditions of either low or high stringency different from, but equivalent to, the above listed conditions.

The term "substantially purified", as used herein, refers to nucleic or amino acid sequences that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated.

A "substitution", as used herein, refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Transformation", as defined herein, describes a process by which exogenous DNA enters and changes a recipient cell. It may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. Such "transformed" cells include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome. They also include cells which transiently express the inserted DNA or RNA for limited periods of time.

A "variant" of HSCS-1, as used herein, refers to an amino acid sequence that is altered by one or more amino acids. The variant may have "conservative" changes,

wherein a substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, e.g., replacement of a glycine with a tryptophan. Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

THE INVENTION

10 The invention is based on the discovery of a new human suppressor of cytokine signaling (hereinafter referred to as "HSCS-1"), the polynucleotides encoding HSCS-1, and the use of these compositions for the diagnosis, prevention, or treatment of cancer and immune disorders

Nucleic acids encoding the HSCS-1 of the present invention were first identified in Incyte Clone 2508270 from the mesentery tumor tissue cDNA library (CONUTUT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:2, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 085260 (LIVRNOT01), 1220385, 1218562, and 1218852 (NEUTGMT01), 1332652 (PANCNOT07), 1712749 (PROSNOT16), 2056004 (BEPINOT01), and 2508270 (CONUTUT01).

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:1, as shown in Figure 1. HSCS-1 is 225 amino acids in length and has potential phosphorylation sites for casein kinase II at S₂₇, T₅₂, and S₁₆₉, for protein kinase C at S₁₉, S₂₆, and S₈₃, and for tyrosine kinase at Y₄₇. As shown in Figure 2, HSCS-1 has chemical and structural homology with mouse SOCS-3 (GI 2245388; SEQ ID NO:3). In particular, HSCS-1 and SOCS-3 share 97% identity. An SH2-binding domain extends between approximately residues F₄₆ and P₁₃₄ in both proteins, and the SOCS box is found between residue V₁₃₆ and the C-terminal residue L₂₂₅. All of the potential protein kinase phosphorylation sites found in HSCS-1 are found in SOCS-3. As illustrated by Figs. 3A and 3B, HSCS-1 and SOCS-3 have rather similar hydrophobicity plots. Northern analysis shows the expression of this sequence in various libraries, at least 48% of which are immortalized or cancerous and at least 34% of which involve

inflammation or the immune response. Of particular note is the expression of HSCS-1 in hematopoietic and immune cells (granulocytes, macrophages, promonocytes, lymphocytes, and leukocytes) and in inflammatory conditions (Crohn's disease, ulcerative colitis, rheumatoid arthritis, osteoarthritis, and erythema nodosum).

5 The invention also encompasses HSCS-1 variants. A preferred HSCS-1 variant is one having at least 80%, and more preferably at least 90%, amino acid sequence identity to the HSCS-1 amino acid sequence (SEQ ID NO:1) and which retains at least one biological, immunological or other functional characteristic or activity of HSCS-1. A most preferred HSCS-1 variant is one having at least 95% amino acid sequence identity to
10 SEQ ID NO:1.

The invention also encompasses polynucleotides which encode HSCS-1. Accordingly, any nucleic acid sequence which encodes the amino acid sequence of HSCS-1 can be used to produce recombinant molecules which express HSCS-1. In a particular embodiment, the invention encompasses the polynucleotide comprising the
15 nucleic acid sequence of SEQ ID NO:2 as shown in Figure 1.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding HSCS-1, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible
20 variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring HSCS-1, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode HSCS-1 and its variants are
25 preferably capable of hybridizing to the nucleotide sequence of the naturally occurring HSCS-1 under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding HSCS-1 or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in
30 accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding HSCS-1 and its derivatives without altering the encoded amino acid sequences include the production of

RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences, or fragments thereof, which encode HSCS-1 and its derivatives, entirely by synthetic chemistry. After
5 production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents that are well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding HSCS-1 or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable
10 of hybridizing to the claimed nucleotide sequences, and in particular, those shown in SEQ ID NO:2, under various conditions of stringency as taught in Wahl, G.M. and S.L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 152:507-511).

Methods for DNA sequencing which are well known and generally available in the
15 art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp, Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham, Chicago, IL), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE Amplification System marketed by
20 Gibco/BRL (Gaithersburg, MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the ABI Catalyst and 373 and 377 DNA Sequencers (Perkin Elmer).

The nucleic acid sequences encoding HSCS-1 may be extended utilizing a partial
25 nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed, "restriction-site" PCR, uses universal primers to retrieve unknown sequence adjacent to a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). In particular, genomic DNA is first amplified in the presence of primer to a linker
30 sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an

appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR may also be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. et al. (1988) *Nucleic Acids Res.* 16:8186). The primers may be designed using commercially available software such as OLIGO 4.06
5 Primer Analysis software (National Biosciences Inc., Plymouth, MN), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR
10 template.

Another method which may be used is capture PCR which involves PCR amplification of DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) *PCR Methods Applic.* 1:111-119). In this method, multiple restriction enzyme digestions and ligations may also
15 be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.

Another method which may be used to retrieve unknown sequences is that of Parker, J.D. et al. (1991; *Nucleic Acids Res.* 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinder™ libraries to walk genomic DNA (Clontech,
20 Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions. When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for
25 situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In
30 particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera.

Output/light intensity may be converted to electrical signal using appropriate software (e.g. Genotyper™ and Sequence Navigator™, Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small
5 pieces of DNA which might be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode HSCS-1 may be used in recombinant DNA molecules to direct expression of HSCS-1, fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which
10 encode substantially the same or a functionally equivalent amino acid sequence may be produced, and these sequences may be used to clone and express HSCS-1.

As will be understood by those of skill in the art, it may be advantageous to produce HSCS-1-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can
15 be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter HSCS-1 encoding sequences for a
20 variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon
25 preference, produce splice variants, introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding HSCS-1 may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of HSCS-1 activity, it may be useful to encode a chimeric HSCS-1 protein that can be recognized by a
30 commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the HSCS-1 encoding sequence and the heterologous protein sequence, so that HSCS-1 may be cleaved and purified away from the heterologous

moiety.

In another embodiment, sequences encoding HSCS-1 may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232). Alternatively, the protein itself may be produced using chemical methods to
5 synthesize the amino acid sequence of HSCS-1, or a fragment thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J.Y. et al. (1995) Science 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer).

10 The newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) Proteins, Structures and Molecular Principles, WH Freeman and Co., New York, NY). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; Creighton, supra). Additionally, the amino acid sequence
15 of HSCS-1, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

In order to express a biologically active HSCS-1, the nucleotide sequences encoding HSCS-1 or functional equivalents, may be inserted into appropriate expression
20 vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding HSCS-1 and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA
25 techniques, synthetic techniques, and in vivo genetic recombination. Such techniques are described in Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview, NY, and Ausubel, F.M. et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY.

A variety of expression vector/host systems may be utilized to contain and express
30 sequences encoding HSCS-1. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems

infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

- 5 The invention is not limited by the host cell employed.

The "control elements" or "regulatory sequences" are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any
10 number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript® phagemid (Stratagene, LaJolla, CA) or pSport1™ plasmid (Gibco BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers
15 derived from the genomes of plant cells (e.g., heat shock, RUBISCO; and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell line that contains multiple copies of the sequence encoding HSCS-1, vectors based on SV40 or EBV may be
20 used with an appropriate selectable marker.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for HSCS-1. For example, when large quantities of HSCS-1 are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to,
25 the multifunctional *E. coli* cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding HSCS-1 may be ligated into the vector in frame with sequences for the amino-terminal Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced; pIN vectors (Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors (Promega,
30 Madison, WI) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by

elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

In the yeast, Saccharomyces cerevisiae, a number of vectors containing constitutive
5 or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) *Methods Enzymol.* 153:516-544.

In cases where plant expression vectors are used, the expression of sequences encoding HSCS-1 may be driven by any of a number of promoters. For example, viral
10 promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell*
15 *Differ.* 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L.E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, NY; pp. 191-196.

20 An insect system may also be used to express HSCS-1. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequences encoding HSCS-1 may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful
25 insertion of HSCS-1 will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, S. frugiperda cells or Trichoplusia larvae in which HSCS-1 may be expressed (Engelhard, E.K. et al. (1994) *Proc. Nat. Acad. Sci.* 91:3224-3227).

In mammalian host cells, a number of viral-based expression systems may be
30 utilized. In cases where an adenovirus is used as an expression vector, sequences encoding HSCS-1 may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3

region of the viral genome may be used to obtain a viable virus which is capable of expressing HSCS-1 in infected host cells (Logan, J. and Shenk, T. (1984) *Proc. Natl. Acad. Sci.* 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

5 Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of 6 to 10M are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes.

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding HSCS-1. Such signals include the ATG initiation codon and adjacent
10 sequences. In cases where sequences encoding HSCS-1, its initiation codon, and upstream sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals
15 including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described
20 in the literature (Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational
25 processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; Bethesda, MD) and may be chosen to ensure the correct modification
30 and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express HSCS-1 may be transformed using

expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable
5 marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines.
10 These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980) Cell 22:817-23) genes which can be employed in tk⁻ or apr⁻ cells, respectively. Also, antimetabolite, antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al.
15 (1980) Proc. Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al (1981) J. Mol. Biol. 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or
20 hisD, which allows cells to utilize histinol in place of histidine (Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins, β glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression
25 attributable to a specific vector system (Rhodes, C.A. et al. (1995) Methods Mol. Biol. 55:121-131).

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding HSCS-1 is inserted within a marker gene sequence,
30 transformed cells containing sequences encoding HSCS-1 can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding HSCS-1 under the control of a single promoter. Expression of the

marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells which contain the nucleic acid sequence encoding HSCS-1 and express HSCS-1 may be identified by a variety of procedures known to those of skill
5 in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

The presence of polynucleotide sequences encoding HSCS-1 can be detected by
10 DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding HSCS-1. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the sequences encoding HSCS-1 to detect transformants containing DNA or RNA encoding HSCS-1.

A variety of protocols for detecting and measuring the expression of HSCS-1,
15 using either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on HSCS-1 is preferred, but a competitive binding assay may be employed. These and other
20 assays are described, among other places, in Hampton, R. et al. (1990; Serological Methods, a Laboratory Manual, APS Press, St Paul, MN) and Maddox, D.E. et al. (1983; J. Exp. Med. 158:1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for
25 producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding HSCS-1 include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding HSCS-1, or any fragments thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be
30 used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, MI); Promega

(Madison WI); and U.S. Biochemical Corp., Cleveland, OH). Suitable reporter molecules or labels, which may be used for ease of detection, include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

5 Host cells transformed with nucleotide sequences encoding HSCS-1 may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode
10 HSCS-1 may be designed to contain signal sequences which direct secretion of HSCS-1 through a prokaryotic or eukaryotic cell membrane. Other constructions may be used to join sequences encoding HSCS-1 to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as
15 histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and HSCS-1
20 may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing HSCS-1 and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMAC (immobilized metal ion affinity chromatography as described in Porath, J. et al. (1992, Prot. Exp. Purif. 3: 263-281) while the enterokinase cleavage site
25 provides a means for purifying HSCS-1 from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. et al. (1993; DNA Cell Biol. 12:441-453).

In addition to recombinant production, fragments of HSCS-1 may be produced by direct peptide synthesis using solid-phase techniques Merrifield J. (1963) J. Am. Chem.
30 Soc. 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Various fragments of HSCS-1 may

be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

THERAPEUTICS

5 Chemical and structural homology exists between HSCS-1 and suppressor of cytokine signaling, SOCS-3 from mouse GI 2245388. In addition, HSCS-1 is expressed in cancer and immortalized cell lines and tissues associated with inflammation and the immune response. Therefore, HSCS-1 appears to play a role in cancer and immune disorders. In particular, decreased expression or activity of HSCS-1 appears to be a
10 associated with the development of these diseases and disorders.

Therefore, in one embodiment, HSCS-1 or a fragment or derivative thereof may be administered to a subject to treat or prevent cancer. Cancers may include, but are not limited to, adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, and teratocarcinoma, and particularly cancers of the adrenal gland, bladder, bone, bone
15 marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus.

In another embodiment, a vector capable of expressing HSCS-1, or a fragment or a derivative thereof, may also be administered to a subject to treat or prevent a cancer,
20 including, but not limited to, the types of cancer described above.

In still another embodiment, an agonist which modulates the activity of HSCS-1 may also be administered to a subject to treat or prevent a cancer including, but not limited to, the types of cancer described above.

In another embodiment, HSCS-1 or a fragment or derivative thereof may be
25 administered to a subject to treat or prevent an immune disorder. Such disorders may include, but are not limited to, AIDS, Addison's disease, adult respiratory distress syndrome, allergies, anemia, asthma, atherosclerosis, bronchitis, cholecystitis, Crohn's disease, ulcerative colitis, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythema nodosum, atrophic gastritis, glomerulonephritis, gout, Graves' disease, hypereosinophilia, irritable bowel syndrome, lupus erythematosus, multiple
30 sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's

syndrome, and autoimmune thyroiditis; complications of cancer, hemodialysis, extracorporeal circulation; viral, bacterial, fungal, parasitic, protozoal, and helminthic infections; and trauma.

In another embodiment, a vector capable of expressing HSCS-1, or a fragment or a derivative thereof, may also be administered to a subject to treat or prevent an immune disorder including, but not limited to, those described above.

In still another embodiment, an agonist which modulates the activity of HSCS-1 may also be administered to a subject to treat or prevent an immune disorder including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of HSCS-1 may be produced using methods which are generally known in the art. In particular, purified HSCS-1 may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind HSCS-1.

Antibodies to HSCS-1 may be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies, (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with HSCS-1 or any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil

emulsions, keyhole limpet hemocyanin, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce
5 antibodies to HSCS-1 have an amino acid sequence consisting of at least five amino acids and more preferably at least 10 amino acids. It is also preferable that they are identical to a portion of the amino acid sequence of the natural protein, and they may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of HSCS-1 amino acids may be fused with those of another protein such as keyhole limpet
10 hemocyanin and antibody produced against the chimeric molecule.

Monoclonal antibodies to HSCS-1 may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler, G. et al. (1975) Nature
15 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. 80:2026-2030; Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120).

In addition, techniques developed for the production of "chimeric antibodies", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with
20 appropriate antigen specificity and biological activity can be used (Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; Takeda, S. et al. (1985) Nature 314:452-454). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce HSCS-1-specific single chain antibodies. Antibodies with
25 related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton D.R. (1991) Proc. Natl. Acad. Sci. 88:11120-3).

Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly
30 specific binding reagents as disclosed in the literature (Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86: 3833-3837; Winter, G. et al. (1991) Nature 349:293-299).

Antibody fragments which contain specific binding sites for HSCS-1 may also be

generated. For example, such fragments include, but are not limited to, the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and
5 easy identification of monoclonal Fab fragments with the desired specificity (Huse, W.D. et al. (1989) Science 254:1275-1281).

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are
10 well known in the art. Such immunoassays typically involve the measurement of complex formation between HSCS-1 and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering HSCS-1 epitopes is preferred, but a competitive binding assay may also be employed (Maddox, supra).

15 In another embodiment of the invention, the polynucleotides encoding HSCS-1, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding HSCS-1 may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding HSCS-1.
20 Thus, complementary molecules or fragments may be used to modulate HSCS-1 activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger fragments, can be designed from various locations along the coding or control regions of sequences encoding HSCS-1.

Expression vectors derived from retro viruses, adenovirus, herpes or vaccinia
25 viruses, or from various bacterial plasmids may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be used to construct vectors which will express nucleic acid sequence which is complementary to the polynucleotides of the gene encoding HSCS-1. These techniques are described both in Sambrook et al. (supra) and in Ausubel et al.
30 (supra).

Genes encoding HSCS-1 can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide or fragment thereof

which encodes HSCS-1. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating
5 vector and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5' or regulatory regions of the gene encoding HSCS-1 (signal sequence, promoters, enhancers, and introns). Oligonucleotides derived from the transcription
10 initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the
15 literature (Gee, J.E. et al. (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific
20 cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples which may be used include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding HSCS-1.

25 Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may
30 render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by
5 in vitro and in vivo transcription of DNA sequences encoding HSCS-1. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues.

10 RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the
15 inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be
20 introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections or polycationic amino polymers (Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-66; incorporated herein by reference) may be achieved using methods which are well known in the art.

25 Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for
30 any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of HSCS-1, antibodies to HSCS-1, mimetics, agonists, antagonists, or inhibitors of HSCS-1. The compositions may be administered alone or in combination with at least

one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

5 The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

 In addition to the active ingredients, these pharmaceutical compositions may
10 contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

15 Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

20 Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice,
25 potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

30 Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer

solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules
5 made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with
10 or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such
15 as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain
20 suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

25 The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with
30 many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may

be a lyophilized powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For
5 administration of HSCS-1, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended
10 purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate
15 concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example HSCS-1 or fragments thereof, antibodies of HSCS-1, agonists, antagonists or inhibitors of HSCS-1, which ameliorates the symptoms or condition. Therapeutic efficacy
20 and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED₅₀ (the dose therapeutically effective in 50% of the population) and LD₅₀ (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD₅₀/ED₅₀. Pharmaceutical compositions which exhibit large therapeutic indices are
25 preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

30 The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may

be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once
5 every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for
10 nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

DIAGNOSTICS

In another embodiment, antibodies which specifically bind HSCS-1 may be used
15 for the diagnosis of conditions or diseases characterized by expression of HSCS-1, or in assays to monitor patients being treated with HSCS-1, agonists, antagonists or inhibitors. The antibodies useful for diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for HSCS-1 include methods which utilize the antibody and a label to detect HSCS-1 in human body fluids or extracts
20 of cells or tissues. The antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules which are known in the art may be used, several of which are described above.

A variety of protocols including ELISA, RIA, and FACS for measuring HSCS-1
25 are known in the art and provide a basis for diagnosing altered or abnormal levels of HSCS-1 expression. Normal or standard values for HSCS-1 expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to HSCS-1 under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, but
30 preferably by photometric means. Quantities of HSCS-1 expressed in subject, control and disease, samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding HSCS-1 may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of HSCS-1 may be correlated with disease. The diagnostic assay may be used to distinguish between absence, presence, and excess expression of HSCS-1, and to monitor regulation of HSCS-1 levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding HSCS-1 or closely related molecules, may be used to identify nucleic acid sequences which encode HSCS-1. The specificity of the probe, whether it is made from a highly specific region, e.g., 10 unique nucleotides in the 5' regulatory region, or a less specific region, e.g., especially in the 3' coding region, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low) will determine whether the probe identifies only naturally occurring sequences encoding HSCS-1, alleles, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably contain at least 50% of the nucleotides from any of the HSCS-1 encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and derived from the nucleotide sequence of SEQ ID NO:2 or from genomic sequence including promoter, enhancer elements, and introns of the naturally occurring HSCS-1.

Means for producing specific hybridization probes for DNAs encoding HSCS-1 include the cloning of nucleic acid sequences encoding HSCS-1 or HSCS-1 derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, radionuclides such as ^{32}P or ^{35}S , or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding HSCS-1 may be used for the diagnosis of conditions or disorders which are associated with expression of HSCS-1. Examples of such conditions or disorders include cancer, such as adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, and teratocarcinoma, and particularly cancers

of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; and immune disorders, such as AIDS, Addison's disease, adult respiratory distress syndrome, allergies, anemia, asthma, atherosclerosis, bronchitis, cholecystitis, Crohn's disease, ulcerative colitis, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythema nodosum, atrophic gastritis, glomerulonephritis, gout, Graves' disease, hypereosinophilia, irritable bowel syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, and autoimmune thyroiditis; complications of cancer, hemodialysis, extracorporeal circulation; viral, bacterial, fungal, parasitic, protozoal, and helminthic infections; and trauma. The polynucleotide sequences encoding HSCS-1 may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; or in dipstick, pin, ELISA assays or microarrays utilizing fluids or tissues from patient biopsies to detect altered HSCS-1 expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding HSCS-1 may be useful in assays that detect activation or induction of various cancers, particularly those mentioned above. The nucleotide sequences encoding HSCS-1 may be labeled by standard methods, and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the biopsied or extracted sample is significantly altered from that of a comparable control sample, the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the presence of altered levels of nucleotide sequences encoding HSCS-1 in the sample indicates the presence of the associated disease. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of disease associated with expression of HSCS-1, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either

animal or human, with a sequence, or a fragment thereof, which encodes HSCS-1, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with those from an experiment where a known amount of a substantially purified polynucleotide is used.

- 5 Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for disease. Deviation between standard and subject values is used to establish the presence of disease.

Once disease is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to evaluate whether the level of expression in the
10 patient begins to approximate that which is observed in the normal patient. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of
15 the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences
20 encoding HSCS-1 may involve the use of PCR. Such oligomers may be chemically synthesized, generated enzymatically, or produced *in vitro*. Oligomers will preferably consist of two nucleotide sequences, one with sense orientation (5'→3') and another with antisense (3'←5'), employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers, or even a
25 degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of HSCS-1 include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated (Melby, P.C. et al.
30 (1993) J. Immunol. Methods, 159:235-244; Duplax, C. et al. (1993) Anal. Biochem. 229-236). The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various

dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, an oligonucleotide derived from any of the polynucleotide sequences described herein may be used as a target in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously (to
5 produce a transcript image), and to identify genetic variants, mutations and polymorphisms. This information will be useful in determining gene function, understanding the genetic basis of disease, diagnosing disease, and in developing and monitoring the activity of therapeutic agents (Heller, R. et al. (1997) *Proc. Natl. Acad. Sci.* 94:2150-55).

10 In one embodiment, the microarray is prepared and used according to the methods described in PCT application WO95/11995 (Chee et al.), Lockhart, D. J. et al. (1996; *Nat. Biotech.* 14: 1675-1680) and Schena, M. et al. (1996; *Proc. Natl. Acad. Sci.* 93: 10614-10619), all of which are incorporated herein in their entirety by reference.

The microarray is preferably composed of a large number of unique, single-
15 stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides in length. For a certain type of microarray, it may be preferable to use oligonucleotides which are only 7-10 nucleotides in length. The
20 microarray may contain oligonucleotides which cover the known 5', or 3', sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence. Polynucleotides used in the microarray may be oligonucleotides that are specific to a gene or genes of interest in which at least a fragment of the sequence is known or that are
25 specific to one or more unidentified cDNAs which are common to a particular cell type, developmental or disease state.

In order to produce oligonucleotides to a known sequence for a microarray, the gene of interest is examined using a computer algorithm which starts at the 5' or more preferably at the 3' end of the nucleotide sequence. The algorithm identifies oligomers of
30 defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray.

The "pairs" will be identical, except for one nucleotide which preferably is located in the center of the sequence. The second oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed
5 chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

In another aspect, an oligonucleotide may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application WO95/251116 (Baldeschweiler et al.) which is incorporated
10 herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array, such as those described above, may be produced by hand or by using available devices (slot blot or dot blot apparatus), materials (any suitable solid
15 support), and machines (including robotic instruments), and may contain 8, 24, 96, 384, 1536 or 6144 oligonucleotides, or any other number between two and one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using a microarray, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is
20 produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray so that the probe sequences hybridize to complementary oligonucleotides of the microarray. Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After
25 removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A
30 detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large scale correlation studies on the sequences, mutations, variants, or polymorphisms

among samples.

In another embodiment of the invention, the nucleic acid sequences which encode HSCS-1 may also be used to generate hybridization probes which are useful for mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular
5 chromosome, to a specific region of a chromosome or to artificial chromosome constructions, such as human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price, C.M. (1993) Blood Rev. 7:127-134, and Trask, B.J. (1991) Trends Genet. 7:149-154.

10 Fluorescent in situ hybridization (FISH as described in Verma et al. (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York, NY) may be correlated with other physical chromosome mapping techniques and genetic map data. Examples of genetic map data can be found in various scientific journals or at Online Mendelian Inheritance in Man (OMIM). Correlation between the location of the gene
15 encoding HSCS-1 on a physical chromosomal map and a specific disease, or predisposition to a specific disease, may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the subject invention may be used to detect differences in gene sequences between normal, carrier, or affected individuals.

In situ hybridization of chromosomal preparations and physical mapping
20 techniques such as linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable
25 information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti, R. A. et al. (1988) Nature 336:577-580), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequence of the
30 subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

In another embodiment of the invention, HSCS-1, its catalytic or immunogenic

fragments or oligopeptides thereof, can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes, between HSCS-1 and the agent
5 being tested, may be measured.

Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, as applied to HSCS-1 large numbers of different small test compounds are synthesized on a
10 solid substrate, such as plastic pins or some other surface. The test compounds are reacted with HSCS-1, or fragments thereof, and washed. Bound HSCS-1 is then detected by methods well known in the art. Purified HSCS-1 can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

15 In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding HSCS-1 specifically compete with a test compound for binding HSCS-1. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with HSCS-1.

In additional embodiments, the nucleotide sequences which encode HSCS-1 may
20 be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

The examples below are provided to illustrate the subject invention and are not
25 included for the purpose of limiting the invention.

EXAMPLES

I CONUTUT01 cDNA Library Construction

The CONUTUT01 cDNA library was constructed from sigmoid mesentery tumor
30 tissue removed from a 61-year old female (specimen #0795) during abdominal excision of multiple tumors. Pathology indicated a metastatic grade 4 malignant mixed mullerian tumor present in the sigmoid mesentery at two sites. Pathology of adjacent tissues

indicated a grade 4 malignant mixed Mullerian tumor of the uterus forming a firm, infiltrating mass throughout the myometrium and involving the serosal surface. The heterologous elements of the tumor consisted of rhabdomyoblasts and immature cartilage. The tumor also involved the lower uterine segment and extended into the cervical wall.

5 Extensive lymphatic and vascular permeation was identified in the myometrium and cervical wall. A single (of 7) right common iliac and a single (of 7) right external iliac lymph nodes were identified with metastatic grade 4 malignant mixed mullerian tumor with the metastases comprised mainly of adenocarcinoma. Estrogen and progesterone receptor studies were positive.

10 The frozen tissue was homogenized and lysed in Trizol reagent (1 gm tissue/10 ml Trizol; Cat. #10296-028; Gibco/BRL), a monoplastic solution of phenol and guanidine isothiocyanate, using a Brinkmann Homogenizer Polytron PT-3000 (Brinkmann Instruments, Westbury, NY). After a brief incubation on ice, chloroform was added (1:5 v/v), and the lysate was centrifuged. The upper chloroform layer was removed to a fresh
15 tube, and the RNA extracted with isopropanol, resuspended in DEPC-treated water, and DNase treated for 25 min at 37°C. The RNA was re-extracted twice with acid phenol-chloroform pH 4.7 and precipitated using 0.3M sodium acetate and 2.5 volumes ethanol. The mRNA was isolated with the Qiagen Oligotex kit (QIAGEN, Inc., Chatsworth, CA) and used to construct the cDNA library.

20 The mRNA was handled according to the recommended protocols in the SuperScript Plasmid System (Cat. #18248-013, Gibco/BRL). CONUTUT01 cDNAs were fractionated on a Sepharose CL4B column (Cat. #275105-01; Pharmacia), and those cDNAs exceeding 400 bp were ligated into pINC Y 1. The plasmid pINC Y 1 was subsequently transformed into DH5a™ competent cells (Cat. #18258-012; Gibco/BRL).

25

II Isolation and Sequencing of cDNA Clones

Plasmid DNA was released from the cells and purified using the REAL Prep 96 Plasmid Kit (Catalog #26173, QIAGEN, Inc.). The recommended protocol was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile Terrific
30 Broth (Catalog #22711; Gibco/BRL) with carbenicillin at 25 mg/L and glycerol at 0.4%; 2) after inoculation, the cultures were incubated for 19 hours and at the end of incubation, the cells were lysed with 0.3 ml of lysis buffer; and 3) following isopropanol precipitation,

the plasmid DNA pellet was resuspended in 0.1 ml of distilled water. After the last step in the protocol, samples were transferred to a 96-well block for storage at 4° C.

The cDNAs were sequenced by the method of Sanger et al. (1975, J. Mol. Biol. 94:441ff), using a Hamilton Micro Lab 2200 (Hamilton, Reno, NV) in combination with
5 Peltier Thermal Cyclers (PTC200 from MJ Research, Watertown, MA) and Applied Biosystems 377 DNA Sequencing Systems; and the reading frame was determined.

III Homology Searching of cDNA Clones and Their Deduced Proteins

The nucleotide sequences and/or amino acid sequences of the Sequence Listing
10 were used to query sequences in the GenBank, SwissProt, BLOCKS, and Pima II databases. These databases, which contain previously identified and annotated sequences, were searched for regions of homology using BLAST, which stands for Basic Local Alignment Search Tool (Altschul, S.F. (1993) J. Mol. Evol 36:290-300; Altschul, et al. (1990) J. Mol. Biol. 215:403-410).

15 BLAST produced alignments of both nucleotide and amino acid sequences to determine sequence similarity. Because of the local nature of the alignments, BLAST was especially useful in determining exact matches or in identifying homologs which may be of prokaryotic (bacterial) or eukaryotic (animal, fungal, or plant) origin. Other algorithms such as the one described in Smith, T. et al. (1992, Protein Engineering 5:35-51),
20 incorporated herein by reference, could have been used when dealing with primary sequence patterns and secondary structure gap penalties. The sequences disclosed in this application have lengths of at least 49 nucleotides, and no more than 12% uncalled bases (where N is recorded rather than A, C, G, or T).

The BLAST approach searched for matches between a query sequence and a
25 database sequence. BLAST evaluated the statistical significance of any matches found, and reported only those matches that satisfy the user-selected threshold of significance. In this application, threshold was set at 10^{-25} for nucleotides and 10^{-14} for peptides.

Incyte nucleotide sequences were searched against the GenBank databases for primate (pri), rodent (rod), and other mammalian sequences (mam); and deduced amino
30 acid sequences from the same clones were then searched against GenBank functional protein databases, mammalian (mamp), vertebrate (vrtp), and eukaryote (eukp) for homology.

IV Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound

5 (Sambrook et al., supra).

Analogous computer techniques using BLAST (Altschul, S.F. (1993) J.Mol.Evol. 36:290-300; Altschul, S.F. et al. (1990) J.Mol.Evol. 215:403-410) are used to search for identical or related molecules in nucleotide databases such as GenBank or the LIFESEQ™ database (Incyte Pharmaceuticals). This analysis is much faster than multiple, membrane-
10 based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

The basis of the search is the product score which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

15 The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1-2% error; and at 70, the match will be exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

20 The results of northern analysis are reported as a list of libraries in which the transcript encoding HSCS-1 occurs. Abundance and percent abundance are also reported. Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences examined in the cDNA library.

25

V Extension of HSCS-1 Encoding Polynucleotides

The nucleic acid sequence of the Incyte Clone 2508270 was used to design oligonucleotide primers for extending a partial nucleotide sequence to full length. One primer was synthesized to initiate extension in the antisense direction, and the other was
30 synthesized to extend sequence in the sense direction. Primers were used to facilitate the extension of the known sequence "outward" generating amplicons containing new, unknown nucleotide sequence for the region of interest. The initial primers were designed

from the cDNA using OLIGO 4.06 (National Biosciences), or another appropriate program, to be about 22 to about 30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures of about 68° to about 72° C.

Any stretch of nucleotides which would result in hairpin structures and primer-primer
5 dimerizations was avoided.

Selected human cDNA libraries (Gibco/BRL) were used to extend the sequence. If more than one extension is necessary or desired, additional sets of primers are designed to further extend the known region.

High fidelity amplification was obtained by following the instructions for the XL-
10 PCR kit (Perkin Elmer) and thoroughly mixing the enzyme and reaction mix. Beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, PCR was performed using the Peltier Thermal Cycler (PTC200; M.J. Research, Watertown, MA) and the following parameters:

	Step 1	94° C for 1 min (initial denaturation)
15	Step 2	65° C for 1 min
	Step 3	68° C for 6 min
	Step 4	94° C for 15 sec
	Step 5	65° C for 1 min
	Step 6	68° C for 7 min
20	Step 7	Repeat step 4-6 for 15 additional cycles
	Step 8	94° C for 15 sec
	Step 9	65° C for 1 min
	Step 10	68° C for 7:15 min
	Step 11	Repeat step 8-10 for 12 cycles
25	Step 12	72° C for 8 min
	Step 13	4° C (and holding)

A 5-10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a low concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were
30 successful in extending the sequence. Bands thought to contain the largest products were excised from the gel, purified using QIAQuick™ (QIAGEN Inc., Chatsworth, CA), and trimmed of overhangs using Klenow enzyme to facilitate religation and cloning.

After ethanol precipitation, the products were redissolved in 13 μ l of ligation buffer, 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase were added, and
35 the mixture was incubated at room temperature for 2-3 hours or overnight at 16° C. Competent *E. coli* cells (in 40 μ l of appropriate media) were transformed with 3 μ l of

ligation mixture and cultured in 80 μ l of SOC medium (Sambrook et al., supra). After incubation for one hour at 37° C, the *E. coli* mixture was plated on Luria Bertani (LB)-agar (Sambrook et al., supra) containing 2x Carb. The following day, several colonies were randomly picked from each plate and cultured in 150 μ l of liquid LB/2x Carb medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture was transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5 μ l of each sample was transferred into a PCR array.

For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers used for the extension reaction were added to each well. Amplification was performed using the following conditions:

	Step 1	94° C for 60 sec
	Step 2	94° C for 20 sec
15	Step 3	55° C for 30 sec
	Step 4	72° C for 90 sec
	Step 5	Repeat steps 2-4 for an additional 29 cycles
	Step 6	72° C for 180 sec
20	Step 7	4° C (and holding)

Aliquots of the PCR reactions were run on agarose gels together with molecular weight markers. The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid, and sequenced.

In like manner, the nucleotide sequence of SEQ ID NO:2 is used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for 5' extension, and an appropriate genomic library.

VI Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:2 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base-pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250 μ Ci of [γ -³²P] adenosine triphosphate (Amersham) and T4

polynucleotide kinase (DuPont NEN®, Boston, MA). The labeled oligonucleotides are substantially purified with Sephadex G-25 superfine resin column (Pharmacia & Upjohn). A aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases (Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II; DuPont NEN®).

The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham, NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR™ film (Kodak, Rochester, NY) is exposed to the blots in a Phosphorimager cassette (Molecular Dynamics, Sunnyvale, CA) for several hours, hybridization patterns are compared visually.

VII Microarrays

To produce oligonucleotides for a microarray, the nucleotide sequence described herein is examined using a computer algorithm which starts at the 3' end of the nucleotide sequence. The algorithm identifies oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that would interfere with hybridization. The algorithm identifies sequence-specific oligonucleotides of 20 nucleotides in length (20-mers). A matched set of oligonucleotides is created in which one nucleotide in the center of each sequence is altered. This process is repeated for each gene in the microarray, and double sets of twenty 20 mers are synthesized and arranged on the surface of the silicon chip using a light-directed chemical process (Chee, M. et al., PCT/WO95/11995, incorporated herein by reference).

In the alternative, a chemical coupling procedure and an ink jet device are used to synthesize oligomers on the surface of a substrate (Baldeschweiler, J.D. et al., PCT/WO95/25116, incorporated herein by reference). In another alternative, a "gridded" array analogous to a dot (or slot) blot is used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array may be produced by hand or using

available materials and machines and contain grids of 8 dots, 24 dots, 96 dots, 384 dots, 1536 dots or 6144 dots. After hybridization, the microarray is washed to remove nonhybridized probes, and a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity
5 and the relative abundance of each oligonucleotide sequence on the micro-array.

VIII Complementary Polynucleotides

Sequence complementary to the HSCS-1-encoding sequence, or any part thereof, is used to decrease or inhibit expression of naturally occurring HSCS-1. Although use of
10 oligonucleotides comprising from about 15 to about 30 base-pairs is described, essentially the same procedure is used with smaller or larger sequence fragments. Appropriate oligonucleotides are designed using Oligo 4.06 software and the coding sequence of HSCS-1, SEQ ID NO:1. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the
15 coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the HSCS-1-encoding transcript.

IX Expression of HSCS-1

Expression of HSCS-1 is accomplished by subcloning the cDNAs into appropriate
20 vectors and transforming the vectors into host cells. In this case, the cloning vector is also used to express HSCS-1 in *E. coli*. Upstream of the cloning site, this vector contains a promoter for β -galactosidase, followed by sequence containing the amino-terminal Met, and the subsequent seven residues of β -galactosidase. Immediately following these eight residues is a bacteriophage promoter useful for transcription and a linker containing a
25 number of unique restriction sites.

Induction of an isolated, transformed bacterial strain with IPTG using standard methods produces a fusion protein which consists of the first eight residues of
- β -galactosidase, about 5 to 15 residues of linker, and the full length protein. The signal residues direct the secretion of HSCS-1 into the bacterial growth media which can be used
30 directly in the following assay for activity.

X Demonstration of HSCS-1 Activity

HSCS-1 activity is demonstrated by the inhibition of differentiation in murine M1 cells transfected with the gene expressing HSCS-1 and induced to differentiate by treatment with IL-6 (Starr et al., supra). Differentiation is measured in the parent M1 cell line and in M1 cells transfected with HSCS-1 by the appearance of differentiated colonies in cells grown in semi-soft agar culture. The percent inhibition of differentiation in M1 transfected cells compared to the parent M1 cell line is proportional to the activity of HSCS-1 in the former cells.

XI Production of HSCS-1 Specific Antibodies

HSCS-1 that is substantially purified using PAGE electrophoresis (Sambrook, supra), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols. The amino acid sequence deduced from SEQ ID NO:2 is analyzed using DNASTAR software (DNASTAR Inc) to determine regions of high immunogenicity and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is described by Ausubel et al. (supra), and others.

Typically, the oligopeptides are 15 residues in length, synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry, and coupled to keyhole limpet hemocyanin (KLH, Sigma, St. Louis, MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel et al., supra). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio iodinated, goat anti-rabbit IgG.

XII Purification of Naturally Occurring HSCS-1 Using Specific Antibodies

Naturally occurring or recombinant HSCS-1 is substantially purified by immunoaffinity chromatography using antibodies specific for HSCS-1. An immunoaffinity column is constructed by covalently coupling HSCS-1 antibody to an activated chromatographic resin, such as CNBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin is blocked and washed according to the

manufacturer's instructions.

Media containing HSCS-1 is passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of HSCS-1 (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under
5 conditions that disrupt antibody/HSCS-1 binding (eg, a buffer of pH 2-3 or a high concentration of a chaotrope, such as urea or thiocyanate ion), and HSCS-1 is collected.

XIII Identification of Molecules Which Interact with HSCS-1

HSCS-1 or biologically active fragments thereof are labeled with ¹²⁵I
10 Bolton-Hunter reagent (Bolton et al. (1973) Biochem. J. 133: 529). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled HSCS-1, washed and any wells with labeled HSCS-1 complex are assayed. Data obtained using different concentrations of HSCS-1 are used to calculate values for the number, affinity, and association of HSCS-1 with the candidate molecules.

15 All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention
20 as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

What is claimed is:

1. A substantially purified suppressor of cytokine signaling comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof.
- 5 2. A substantially purified variant of suppressor of cytokine signaling having at least 90% amino acid identity to SEQ ID NO:1 and which retains at least one functional characteristic of a suppressor of cytokine signaling.
- 10 3. An isolated and purified polynucleotide sequence encoding the suppressor of cytokine signaling of claim 1 or fragments or variants of said polynucleotide sequence.
4. A composition comprising the polynucleotide sequence of claim 3.
- 15 5. An isolated and purified polynucleotide sequence which hybridizes to the polynucleotide sequence of claim 3.
6. An isolated and purified polynucleotide sequence which is complementary to the polynucleotide sequence of claim 3 or fragments or variants thereof.
- 20 7. An isolated and purified polynucleotide sequence comprising SEQ ID NO:2 or fragments or variants thereof.
8. A polynucleotide sequence which is complementary to the polynucleotide
25 sequence of claim 7.
9. An expression vector containing at least a fragment of the polynucleotide sequence of claim 3.
- 30 10. A host cell containing the expression vector of claim 9.
11. A method for producing a polypeptide comprising the amino acid sequence

of SEQ ID NO:1, or a fragment thereof, the method comprising the steps of:

- a) culturing the host cell of claim 10 under conditions suitable for the expression of the polypeptide; and
- b) recovering the polypeptide from the host cell culture.

5

12. A pharmaceutical composition comprising a substantially purified suppressor of cytokine signaling having the amino acid sequence of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.

10 13. A purified antibody which specifically binds to the polypeptide of claim 1.

14. A purified agonist of the polypeptide of claim 1.

15. A purified antagonist of the polypeptide of claim 1.

15

16. A method for treating a cancer comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 12.

17. A method for treating an immune disorder comprising administering to a
20 subject in need of such treatment an effective amount of the pharmaceutical composition of claim 12.

18. A method for detecting a polynucleotide which encodes a suppressor of cytokine signaling in a biological sample comprising the steps of:

- 25 a) hybridizing the polynucleotide of claim 6 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and
- b) detecting said hybridization complex, wherein the presence of the complex correlates with the presence of a polynucleotide encoding the suppressor of cytokine signaling in the biological sample.

30

19. The method of claim 18 wherein the nucleic acid material is amplified by the polymerase chain reaction prior to hybridization.

1/9

9 18 27 36 45 54
 NNG TGN CCG CTG TGN ANG NGC CNG ATN NGC GGA GGC CGC GAA CAG CTG CAG CCG

63 72 81 90 99 108
 CCG CCG CGC AGA TCC ACG CTG GCT CCG TGC GCC ATG GTC ACC CAC AGC AAG TTT
 M V T H S K F

117 126 135 144 153 162
 CCC GCC GCC GGG ATG AGC CGC CCC CTG GAC ACC AGC CTG CGC CTC AAG ACC TTC
 P A A G M S R P L D T S L R L K T F

171 180 189 198 207 216
 AGC TCC AAG AGC GAG TAC CAG CTG GTG AAG AAC GCA GTG CGC AAG CTG CAG GAG
 S S K S E Y Q L V V N A V R K L Q E

225 234 243 252 261 270
 AGC GGC TTC TAC TGG AGC GCA GTG ACC GGC GGC GAG GCG AAC CTG CTG CTC AGT
 S G F Y W S A V T G G E A N L L L S

279 288 297 306 315 324
 GCC GAG CCC GCC ACC TTT CTG ATC CGC GAC AGC TCG GAC CAG CGC CAC TTC
 A E P A G T F L I R D S S D Q R H F

333 342 351 360 369 378
 TTC ACG CTC AGC GTC AAG ACC CAG TCT GGG ACC AAG AAC CTG CGC ATC CAG TGT
 F T L S V K T Q S G T K N L R I Q C

FIGURE 1A

3/9

765	774	783	792	801	810
CCG CTT TAA GGG GTA AAG GGC GCA AAG GGC ATG GGT CGG GAG AGG GGA CGC AGG					
P L					
819	828	837	846	855	864
CCC CTC TCC TTC CGT GGC ACA TGG CAC AAG CAC AAG AAG CCA ACC AGG AGA GAG					
873	882	891	900	909	918
TCC TGT AGC TCT GGG GGC AAA GAG GGC GGA CAG GCC CCT CCC TCT GCC CTC TCC					
927	936	945	954	963	972
CTG CAG AAT GTG GCA GGC GGA CCT GGA ATG TGT TGG AGG GAA GGG GGA GTA CCA					
981	990	999	1008	1017	1026
CCT GAG TCT CCA GCT TCT CCG GAG GAG CCA GCT GTC CTG GTG GGA CGA TAG CAA					
1035	1044	1053	1062	1071	1080
CCA CAA GTG GAT TCT CCT TCA ATT CCT CAG CAG CTT CCC CTC TGC CTC CAA ACA GGG					
1089	1098	1107	1116	1125	1134
GAC ACT TCG GGA ATG CTG AAC TAA TGA GAA CTG CCA GGG AAT CTT CAA ACT TTC					
1143	1152	1161	1170	1179	1188
CAA CGG AAC TTG TTT GCT CTT TGA TTT GST TTA AAC CTG AGC TCG TTG TGG AGC					
1197	1206	1215	1224	1233	1242
CTG GGA AAG GTG GAA GAG AGA GAG GTC CTG AGG GGC CCA GGG CTG CGG GCT GGC					

FIGURE 1C

4/9

1251	1260	1269	1278	1287	1296
GAA GGA AAT GGT CAC ACC CCC CGC CCA CCC CAG GCG AGG ATC CTG GTG ACA TGC					
1305	1314	1323	1332	1341	1350
TCC TCT CCC TGG CTC CGG GGA GAA GGG CTT GGG GTG ACC TGA AGG GAA CCA TCC					
1359	1368	1377	1386	1395	1404
TGG GTA CCC CAC ATC CTC TCC TCC GGG ACA GTC ACC GAA AAC ACA GGT TCC AAA					
1413	1422	1431	1440	1449	1458
GTC TAC CTG GTG CCT GAG AGC CCA GGG CCC TTC CTC CGT TTT AAG GGG GAA GCA					
1467	1476	1485	1494	1503	1512
ACA TTT GGA GGG GAC GGA TGG GCT GGT CAG CTG GTC TCC TTT TCC TAC TCA TAC					
1521	1530	1539	1548	1557	1566
TAT ACC TTC CTG TAC CTG GGT GGA TGG AGC GGG AGG ATG GAG GAG ACG GGA CAT					
1575	1584	1593	1602	1611	1620
CTT TCA CCT CAG GCT CCT GGT AGA GAA GAC AGG GGA TTC TAC TCT GTG CCT CCT					
1629	1638	1647	1656	1665	1674
GAC TAT GTC TGG CTA AGA GAT TCG CCT TAA ATG CTC CCT CTC CCA TGG AGA GGG					
1683	1692	1701	1710	1719	1728
ACC CAG CAT AGG AAA GCC ACA TAC TCA GCC TGG ATG GGT GGA GAG GCT GAG GGA					

FIGURE 1D

5/9

1737	1746	1755	1764	1773	1782
CTC ACT GGA GGG CAC CAA GCC AGC CCA CAG CCA GGG AAG TGG GGA GGG GGG GCG					
1791	1800	1809	1818	1827	1836
GAA ACC CAT GCC TCC CAG CTG AGC ACT GGG AAT GTC AGC CCA GTA AGT APT GGC					
1845	1854	1863	1872	1881	1890
CAG TCA GGC GCC TCG TGG TCA GAG CAG AGC CAC CAG GTC CCA CTG CCC CGA GCC					
1899	1908	1917	1926	1935	1944
CTG CAC AGC CCT CCC TCC TGC CTG GGT GGG GGA GGC TGG AGG TCA TTG GAG AGG					
1953	1962	1971	1980	1989	1998
CTG GAC TGC TGC CAC CCC GGG TGC TCC CGC TCT GCC ATA GCA CTG ATC AGT GAC					
2007	2016	2025	2034	2043	2052
AAT TTA CAG GAA TGT AGC AGC GAT GGA APT ACC TGG AAC AGT TTT TTG TTT TTG					
2061	2070	2079	2088	2097	2106
TTT TTG TTT TTG TTT TTG TGG GGG GCA ACT AAA CAA ACA CAA AGT APT CTG					
2115	2124	2133	2142	2151	2160
TGT CAG GTA TTG GGC TGG ACA GGG CAG TTG TGT GGT GGG GTG GTT TTT TTC TCT					
2169	2178	2187	2196	2205	2214
ATT TTT TTG TTT GPT TCT TGT TTT TTA ATA ATG TTT ACA ATC TGC CTC AAT CAC					

FIGURE 1E

6/9

2223 2232 2241 2250 2259 2268
TCT GTC TTT TAT AAA GAT TCC ACC TCC AGT CCT CTC TCC TCC CCC CTA CTC AGG

2277 2286 2295 2304 2313 2322
CCC TTG AGG CTA TTA GGA GAT GCT TGA AGA ACT CAA CAA AAT CCC AAT CCA AGT

2331 2340 2349 2358 2367 2376
CAA ACT TTG CAC ATA TTT ATA TTC AGA AAA GAA ACA TTT CAG TAA TTT

2385 2394
ATA ATA AAG AGC ACT ATT TTT TAA TG

FIGURE 1F

1	MVTHSKFPAAAGMSRPLDTSRLRLKTFSSKSEYQLVVN	2508270
1	MVTHSKFPAAAGMSRPLDTSRLRLKTFSSKSEYQLVVN	g2245388
41	LQESGFYWSAVTGGGEANLLLSAEPAGTFLIRDSSDQRHFF	2508270
41	LQESGFYWSAVTGGGEANLLLSAEPAGTFLIRDSSDQRHFF	g2245388
81	TL SVK TQSGT KNLRIQCEGGSFSLQSDP RSTQPVPRFDCV	2508270
81	TL SVK TQSGT KNLRIQCEGGSFSLQSDP RSTQPVPRFDCV	g2245388
121	LKLVHHYMP PPGAPSEFPSPPT EPPSSSEVP EQPSAQPLPGSP	2508270
121	LKLVHHYMP PPGT PSESLPPPT EPPSSSEVP EQP PAQALPGST	g2245388
161	PRRAYYIYSGGGEKIPLVL SRRPLSSNVATLQHLCRKTVNGH	2508270
161	PKRAYYIYSGGGEKIPLVL SRRPLSSNVATLQHLCRKTVNGH	g2245388
201	LDSEYEKVTQLPGPIREFFLDQYDAPL	2508270
201	LDSEYEKVTQLPGPIREFFLDQYDAPL	g2245388

7/9

FIGURE 2

8/9




FIGURE 3A

9/9




FIGURE 3B

PF-0415 PCT

SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.
HILLMAN, Jennifer L.
SHAH, Purvi
CORLEY, Neil C.

<120> SUPPRESSOR OF CYTOKINE SIGNALING

<130> PF-0415 PCT

<140> To Be Assigned

<141> Herewith

<150> 08/963,165

<151> 1997-11-03

<160> 3

<170> PERL PROGRAM

<210> 1

<211> 225

<212> PRT

<213> Homo sapiens

<220> -

<223> 2508270

<400> 1

Met Val Thr His Ser Lys Phe Pro Ala Ala Gly Met Ser Arg Pro
1 5 10 15
Leu Asp Thr Ser Leu Arg Leu Lys Thr Phe Ser Ser Lys Ser Glu
20 25 30
Tyr Gln Leu Val Val Asn Ala Val Arg Lys Leu Gln Glu Ser Gly
35 40 45
Phe Tyr Trp Ser Ala Val Thr Gly Gly Glu Ala Asn Leu Leu Leu
50 55 60
Ser Ala Glu Pro Ala Gly Thr Phe Leu Ile Arg Asp Ser Ser Asp
65 70 75
Gln Arg His Phe Phe Thr Leu Ser Val Lys Thr Gln Ser Gly Thr
80 85 90

PF-0415 PCT

SEQUENCE LISTING

Lys Asn Leu Arg Ile Gln Cys Glu Gly Gly Ser Phe Ser Leu Gln
 95 100 105
 Ser Asp Pro Arg Ser Thr Gln Pro Val Pro Arg Phe Asp Cys Val
 110 115 120
 Leu Lys Leu Val His His Tyr Met Pro Pro Gly Ala Pro Ser
 125 130 135
 Phe Pro Ser Pro Pro Thr Glu Pro Ser Ser Glu Val Pro Glu Gln
 140 145 150
 Pro Ser Ala Gln Pro Leu Pro Gly Ser Pro Pro Arg Arg Ala Tyr
 155 160 165
 Tyr Ile Tyr Ser Gly Gly Glu Lys Ile Pro Leu Val Leu Ser Arg
 170 175 180
 Pro Leu Ser Ser Asn Val Ala Thr Leu Gln His Leu Cys Arg Lys
 185 190 195
 Thr Val Asn Gly His Leu Asp Ser Tyr Glu Lys Val Thr Gln Leu
 200 205 210
 Pro Gly Pro Ile Arg Glu Phe Leu Asp Gln Tyr Asp Ala Pro Leu
 215 220 225

<210> 2

<211> 2400

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> 4, 13, 15, 17, 21, 25, 26

<223> a or g or c or t, unknown, or other

<220> -

<223> 2508270

<400> 2

gtgncgcgtg tgnangnce ngatnngcgg aggccegegaa cagctgcage cgcgcgcgcg 60
 cagatccacg ctggtccgti ggcacatggt caccacacgc aagtttcccg ccgcgcggat 120
 gagecgcgcc ctggacacca gctgcgcct caagaccitc agctccaga gcagatacca 180
 gctggtggtg aacgcagtgc gcaagctgca ggagagcgcg tctactgga gcgcagtgac 240
 cggcgcgcag gcgaacctgc tctcagtgcc cagagccgcc ggcaccitc tgateccgca 300
 cagctcggac cagcgcact tcttacct cagctcag acccagctg ggaccaagaa 360
 cctgcgcate cagtgtgagg ggggcagctt ctctctgcag agcgatccc ggagcacgca 420
 gcccgtgcc cgttcgaet gctgtctca gctggtgcac caataatgc cgcctccgg 480
 agccctccc ttcctctgc caactactga accctctcc gaggtgcgc agcagccgtc 540
 tgcaccaca ctcctggga gtcctccag aagagctat tacatctact ccgggggcga 600
 gaagatccc ctggtgtga gcgcgcct ctctccaac gtgcccact ttcagctct 660

PF-0415 PCT

SEQUENCE LISTING

ctgttgggaag accgtcaacg gccacctgga ctctatgag aaagtcacc agctgcccgg 720
 gccctacgg gagtctctgg accagtaaga tgcctccgtt taagggttaa agggcgcaaa 780
 gggcatgggt cgggagaggg gacgcaggcc cctccttc cgtggcaca ggcacaaaga 840
 caagaagcca accaggagag agtctctag ctctggggg aaagaggcg gacaggccc 900
 tccctctgc cctccctgc agaattggc aggcggact ggaattgtt ggagggaagg 960
 ggggagtaaa cctgagtc cagctctcc ggaggagcca gctctctgg tgggacgata 1020
 gcaaccacaa gtggatttc ctcaattcc tcaactccc ctcgctcc aaacaggga 1080
 cacttggga atgtgaat aatgagaat gccagggaat ctcaactt tcaacggaa 1140
 ctgtttgt cttgattg gtttaacct gacgtgtt tggagcctgg gaaaggtgga 1200
 agagagagag gtcctgagg cccagggtt ggggctggc gaaggaaatg gtcacccc 1260
 cggcccacc caggcgagga tctgttgac agtctctt cctggctcc ggggagaagg 1320
 gcttgggtg acctgaagg aaccatctg ggaacccac atctctct cgggacagt 1380
 caacgaaac acaggttca agtctactt ggtgctgag agccagggc cctctctg 1440
 tttaagggtg gaagcaaat ttgagggtg cggatgggt gttcagctg tctcttct 1500
 ctactatac tatacttcc tgaactggg tggatggag gggagatgg aggagacgg 1560
 acatcttca cctcaggct cgttgagga agacaggga ttactctg tgcctctga 1620
 ctatcttgg ctatgagat cgccttaat gctcctgt ccatggagag ggaccagca 1680
 taggaaagcc acatactag cctgagtg tggagaggt gaggagaca ctggaggga 1740
 ccaagccag ccaagccag ggaattggg agggggggc gaaacccag cctccagct 1800
 gaggactgg aatgacgc cagtaagt ttggcagca ggcgcctct ggtcagagca 1860
 gaggccag gtcactgc cccagccct gcacagcc cctctctg tgggtgggg 1920
 aggtggag tcatggga ggtggact ctcacccc ggtgtctcc gctctgcat 1980
 agcactgac agtgacaat tacaggaat tagcagcat ggaattacct ggaacagt 2040
 ttgttttt ttgttttt ttgttttt gggggggg actaaacaa cacaagtat 2100
 tctgttcag gtaattggc gacaggga gttgtgtt ggggtggt ttctctat 2160
 ttgttttt gttctgtt tttaaat tttaaac tgcctaac actctgt 2220
 ttataagat tcaactcca gctctctc ctcaccca ctacagcc tgggtat 2280
 agagaggt tgaagaact acaaaatc caatccagt caacttgc acatatt 2340
 attatatt agaaagaaa cattcagta attataata agagacata tttaagt 2400

<210> 3

<211> 225

<212> PRT

<213> Mus musculus

<220> -

<223> g2245388

<400> 3

Met Val Thr His Ser Lys Phe Pro Ala Ala Gly Met Ser Arg Pro

1 5 10 15

Leu Asp Thr Ser Leu Arg Leu Lys Thr Phe Ser Ser Lys Ser Glu

20 25 30

Tyr Gln Leu Val Val Asn Ala Val Arg Lys Leu Gln Glu Ser Gly

35 40 45

PF-0415 PCT

SEQUENCE LISTING

Phe Tyr Trp Ser Ala Val Thr Gly Gly Glu Ala Asn Leu Leu Leu
 50 55 60
 Ser Ala Glu Pro Ala Gly Thr Phe Leu Ile Arg Asp Ser Ser Asp
 65 70 75
 Gln Arg His Phe Phe Thr Leu Ser Val Lys Thr Gln Ser Gly Thr
 80 85 90
 Lys Asn Leu Arg Ile Gln Cys Glu Gly Gly Ser Phe Ser Leu Gln
 95 100 105
 Ser Asp Pro Arg Ser Thr Gln Pro Val Pro Arg Phe Asp Cys Val
 110 115 120
 Leu Lys Leu Val His His Tyr Met Pro Pro Pro Gly Thr Pro Ser
 125 130 135
 Phe Ser Leu Pro Pro Thr Glu Pro Ser Ser Glu Val Pro Glu Gln
 140 145 150
 Pro Pro Ala Gln Ala Leu Pro Gly Ser Thr Pro Lys Arg Ala Tyr
 155 160 165
 Tyr Ile Tyr Ser Gly Gly Glu Lys Ile Pro Leu Val Leu Ser Arg
 170 175 180
 Pro Leu Ser Ser Asn Val Ala Thr Leu Gln His Leu Cys Arg Lys
 185 190 195
 Thr Val Asn Gly His Leu Asp Ser Tyr Glu Lys Val Thr Gln Leu
 200 205 210
 Pro Gly Pro Ile Arg Glu Phe Leu Asp Gln Tyr Asp Ala Pro Leu
 215 220 225

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/22930

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/12 C07K14/47 C12N15/70 C12N1/21 A61K38/17 C07K16/18 C1201/68		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N C07K A61K C12Q		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MASA AKI MASUHARA ET AL.: "Cloning and characterization of novel CIS family genes" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 239, no. 2, 20 October 1997, pages 439-446, XP002095405 ORLANDO, FL US see abstract see page 440, right-hand column, paragraph 4 - page 443, left-hand column, paragraph 1 see page 445, left-hand column, paragraph 2 - page 446, left-hand column, paragraph 2 <div style="text-align: center;">--- -/-</div>	1-13, 16-18
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Z" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center;">3 March 1999</div>		Date of mailing of the international search report <div style="text-align: center;">16/03/1999</div>
Name and mailing address of the ISA European Patent Office, P. B. 5816 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized Officer <div style="text-align: center;">Montero Lopez, B</div>

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/22930

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SEIJIRO MINAMOTO ET AL.: "Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI.2 and SSI-3" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 237, no. 1, 8 August 1997, pages 79-83, XP002095406 ORLANDO, FL US see abstract see page 80, left-hand column, paragraph 5 - page 81, left-hand column, paragraph 1 see page 81, right-hand column, paragraph 2 - page 82, right-hand column, paragraph 3 -----	1-13, 16-18
X	ROBYN STARR ET AL.: "A family of cytokine-inducible inhibitors of signalling" NATURE, vol. 387, no. 6636, 26 June 1997, pages 917-921, XP002085491 LONDON GB cited in the application see the whole document -----	1-13, 16-18
P,X	WO 98 20023 A (THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH) 14 May 1998 see sequences SEQ ID NO:7 and 8 see page 4, line 20 - page 16, line 6 see page 33, line 3 - page 45, line 2 see page 52, line 12 - page 62, line 15; example 12 -----	1-13, 16-18
E	EP 0 877 030 A (SMITHKLINE BECKMAN CORPORATION) 11 November 1998 see page 2, line 47 - page 10, line 18 -----	1-13, 16-18
E	WO 99 03994 A (SCHERING CORPORATION) 28 January 1999 see page 3, line 17 - line 26 see sequence SEQ ID NO:11 -----	1,2
E	WO 99 03993 A (SCHERING CORPORATION) 28 January 1999 see page 3, line 14 - line 23 see sequence SEQ ID NO:21 -----	1,2

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/22930

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 16 and 17
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.: 14, 15
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
Claims relating to agonists and antagonists have not been searched due to
the lack of adequate technical description thereof in the application.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/22930

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9820023 A	14-05-1998	AU 4694397 A	29-05-1998
EP 877030 A	11-11-1998	NONE	
WO 9903994 A	28-01-1999	WO 9903993 A	28-01-1999
WO 9903993 A	28-01-1999	WO 9903994 A	28-01-1999